Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma.

Ann Thorac Surg

Division of Thoracic Surgery, Department of Cardiothoracic Surgery, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York 10021, USA.

Published: August 2007

Background: The ability to accurately predict clinical and pathological response and survival in patients undergoing preoperative chemotherapy may have a significant impact on treatment strategy for esophageal carcinoma. This study assessed the predictive accuracy of clinical response (CR) and positron emission tomography (PET) scanning in determining pathological downstaging and disease free survival (DFS) after chemotherapy.

Methods: This is a retrospective review of patients who underwent chemotherapy prior to complete surgical resection for esophageal carcinoma between 1999 and 2005. Clinical response was correlated with pathological downstaging and survival. For PET scanning, the percent reduction in maxSUV after induction therapy was determined and we identified the optimal threshold of percent reduction in maxSUV for predicting clinical response and pathological downstaging.

Results: Sixty-two patients (52 men, median age 62.3) were evaluated. Thirty-nine patients (62.9%) had either a partial (n = 32) or complete clinical response (n = 7) to induction therapy. The sensitivity, specificity, positive, and negative predictive value of an objective clinical response in predicting downstaging in T and (or) N were 85.7%, 55.9%, 61.5%, and 82.6%, respectively. There was no difference in DFS between responders and nonresponders. The PET sensitivity, specificity, positive, and negative predictive values for predicting pathologic downstaging were 77.8%, 52.9%, 56.8%, and 75%, respectively. Thirty-seven patients (59.7%) had a 50% or greater reduction in the maxSUV of their primary tumor and had a significant improvement in DFS compared with patients with a less than 50% reduction in maxSUV (median DFS time: 35.5 months vs 17.9 months, respectively, p = 0.03). Significantly, 11 patients had a 100% reduction in maxSUV despite the presence of residual tumor.

Conclusions: Complete response and PET appear equivalent in predicting pathological downstaging. However, a 50% reduction in the maxSUV after induction therapy is more significantly associated with improved DFS than CR or pathological downstaging. Additionally, a complete absence of PET signal cannot be equated with a complete pathological response.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.athoracsur.2007.03.094DOI Listing

Publication Analysis

Top Keywords

reduction maxsuv
24
clinical response
20
pathological downstaging
16
esophageal carcinoma
12
induction therapy
12
positron emission
8
response
8
pathological response
8
pet scanning
8
percent reduction
8

Similar Publications

Accurate positron emission tomography (PET) data quantification relies on high-quality input plasma curves, but venous blood sampling may yield poor-quality data, jeopardizing modeling outcomes. In this study, we aimed to recover sub-optimal input functions by using information from the tail (5th-100th min) of curves obtained through the frequent sampling protocol and an input recovery (IR) model trained with reference curves of optimal shape. Initially, we included 170 plasma input curves from eight published studies with clamp [F]-fluorodeoxyglucose PET exams.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to investigate the predictable value of pretreatment (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)F-FDG PET-CT) in radiotherapy (RT) for patients with hepatocellular carcinoma (HCC) or portal vein tumor thrombosis (PVTT).

Materials And Methods: We conducted a retrospective analysis of 36 stage I-IV HCC patients treated with RT. (18)F-FDG PET-CT was performed before RT.

View Article and Find Full Text PDF

Preablative Stimulated Thyroglobulin Levels Can Predict Malignant Potential and Therapeutic Responsiveness of Subcentimeter-Sized, 18F-fluorodeoxyglucose-Avid Cervical Lymph Nodes in Patients With Papillary Thyroid Cancer.

Clin Nucl Med

January 2016

From the *Department of Nuclear Medicine, Chonnam National University Hwasun Hospital, Jeonnam, Republic of Korea; †Department of Nuclear Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea, ‡Department of Radiology, Chonnam National University Hospital, Gwangju, Republic of Korea; §Department of Nuclear Medicine, Chosun University Hospital, Gwangju, Republic of Korea.

Purpose: We investigated the potential value of TSH-stimulated serum thyroglobulin (sTg) to characterize subcentimeter-sized, F-FDG avid cervical lymph nodes (LNs) on 18PET/CT and their responsiveness to 131I ablation therapy (IAT) in patients with papillary thyroid cancer.

Materials And Methods: We enrolled 49 patients who were undergoing total thyroidectomy and had incidentally detected FDG-avid LNs on PET/CT before IAT. According to the follow-up results, FDG-avid LNs were classified into 2 groups: those with metastatic LNs (group A) and those with benign LNs (group B).

View Article and Find Full Text PDF

Objectives: Percutaneous cementoplasty (PC) is used for metastatic bone tumor. Bone metastases patients who are unable to avail regular surgery, because of their poor general condition, undergo PC to gain mechanical stability and pain relief. We evaluated the effect of PC using (18)F-FDG PET-CT and investigated the correlation and predictability between quantitative parameters of (18)F-FDG PET-CT and pain status after PC.

View Article and Find Full Text PDF

Background: The prognostic value of maximum standardized uptake value (maxSUV) on (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) is known for localized pulmonary adenocarcinoma, which is most commonly non-mucinous adenocarcinoma. We examined the validity of thin-section computed tomography (TS-CT) and FDG-PET findings in mucinous adenocarcinoma.

Materials And Methods: TS-CT and FDG-PET were performed on 25 patients with mucinous lung adenocarcinoma that was subsequently resected between January 2009 and March 2013.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!